AptarGroup (ATR)
Materials · packaging and dispensing solutions · NYSE
AptarGroup is a global leader in drug delivery and consumer product dispensing solutions, providing specialized pumps, valves, and packaging for pharmaceutical and consumer goods markets.
What AptarGroup does
AptarGroup is a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing, and active packaging solutions. Its products are used extensively in the pharmaceutical, beauty, personal care, home care, food, and beverage markets. The company provides specialized dispensing systems, such as pumps, closures, and aerosol valves, along with elastomeric components and connected health devices.
Themes: pharmaceutical packaging, drug delivery technology, consumer product dispensing, medical devices, sustainable packaging
Fundamentals
- Price$121.81 as of 2026-10-08 close
- Market cap$7.7B as of 2026-07-27 (share count; price 2026-10-08)
- 1-year return-7.4% 2025-10-08 close $131.61 → 2026-10-08 close $121.81
- P/E22.01 as of 2026-10-08
- Net margin+10.4% FY2025, SEC XBRL
- ROE+14.6% FY2025, SEC XBRL
- Debt / equity0.52 as of 2026-09-03
- Revenue growth (YoY)+8.9% as of 2026-09-03
- Revenue CAGR (3y)+4.4% SEC XBRL
- Beta0.59 as of 2026-09-03
- Last reported earnings2026-07-30 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +1.5%; at least 7 years of non-decreasing per-share dividends (SEC XBRL) — we do not hold the year before it, so the real streak may be longer.
How ATR compares in its sector
- price-to-earnings ratiomiddle range 91 covered Materials peers, as of 2026-10-08
- net profit margintop 25% 125 covered Materials peers, as of 2026-09-03
- operating marginmiddle range 108 covered Materials peers, as of 2026-09-03
- return on equitytop 25% 144 covered Materials peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 127 covered Materials peers
- indicated dividend yieldmiddle range 95 covered Materials peers, as of 2026-09-03
- free cash flow (absolute dollars, latest fiscal year)middle range 122 covered Materials peers, as of FY2025
Position among covered Materials companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
ATR is not currently in any published Top 10 list. Its scores are below.
Top 10 score
50.0 #737 of 1,379 scored · #32 of 73 in Materials
Capital return 68th (consecutive years of dividend increases 7 years, net share count bought back over the year 1.4) and profitability 58th (return on equity 14.6%, operating margin 13.3%); weakest is trend (39th, a strong downtrend, with sellers in control).
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
Dividend coverage (FY2025)
Covered by reported results. In FY2025, ATR's dividend was covered by reported results (earnings payout 31%, free-cash-flow payout 40%). This describes past coverage, not a forecast.
- Earnings payout31% dividends / net income
- Free-cash-flow payout40% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2025 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How AptarGroup looks technically
AptarGroup (ATR) is trading 3.9% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 42 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 32, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 40, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive). It made a new 20-day low about 5 trading days ago. It is 17.1% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 3.9% below its 200-day average, the long-term trend line — a long-term downtrend | -4.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $128.61 | $128.61 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $126.82 | $126.82 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 28 calendar days ago — the swings before that are what the structure reading is measured on | 28 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 129.56. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible downward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 42 trading days ago — a "golden cross", a bullish long-term signal | 42 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 32, with sellers in control | 31.7 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 40, neither overbought (above 70) nor oversold (below 30) | 40.4 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($118.78 to $125.98) — its "stochastic" reading is 42 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 42.1 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive) | 1 session |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $146.91 | $146.91 |
|---|---|---|
| From the 52-week high | it is 17.1% below its 52-week high (its highest price of the past year) | -17.1% |
| Above the 52-week low | it is 18.0% above its 52-week low (its lowest price of the past year) | +18.0% |
| Below the 52-week high | it is 17.1% below its highest point of the past year | 17.1% |
| Since a 20-day breakout | it made a new 20-day low about 5 trading days ago | 5 sessions |
| Since a 55-day breakout | it made a new 55-day low about 5 trading days ago | 5 sessions |
| All-time high | its highest closing price on record is $178.03 (set on 2024-11-11) | $178.03 |
| Given back of the 52-week move | over the past year its closes ranged ($111.94 to $145.72), and it has recovered roughly a quarter of its fall from last year’s high — 29% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $132.82 to $133.90. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 29.2% |
| From the all-time high | it is 31.6% below its all-time high | -31.6% |
| Nearest price level | it is trading 0.5% above a support level at $121.20 — a price it turned at five times since 2025-11-13, most recently on 2026-09-10. Since 2024-10-08 it has 3 such levels below the current price and 13 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.5% |
| All-time low | its lowest closing price on record is $23.43 (set on 2006-07-14) | $23.43 |
| Above the all-time low | it is 419.9% above its all-time low | +419.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 87% of it) | 13th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.28 between its high and its low — about 1.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.28 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $119.35 and $126.92 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $119.35 – $123.13 – $126.92 |
| Typical daily range (% of price) | its price moves about 1.9% in a typical session — among the calmest in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 1.9% |
| Stretch from the 200-day average | it is trading 2.2 daily ranges below its 200-day average price (4.0% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 2.2 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.37× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 1.5% since the prior reading | -1.5% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
4
| Since a doji | 9 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 9 sessions ago |
|---|---|---|
| Since a hammer | 9 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 9 sessions ago |
| Since a bullish engulfing | today it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | today |
| Since a bearish engulfing | 4 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 4 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-10-08 0.4% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.4% |
|---|---|---|
| Gap filled | a 2.4% gap up opened on 2026-08-03 has been "filled" 42 sessions ago — price traded back through the level the gap left behind, and it took 5 sessions to close | 42 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +1.3% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 3.1 percentage points (the stock lost 2.0% while the market gained 1.0%) | -3.1% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 5.8 percentage points (the stock lost 1.9% while the market gained 3.8%) | -5.8% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 20.8 percentage points (the stock lost 3.3% while the market gained 17.5%) | -20.8% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 22.4 percentage points (the stock lost 7.4% while the market gained 15.0%) | -22.4% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, MACD momentum is positive — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 5.6% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 4.1% of the share price. | -5.6% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 4% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $127.02 — a volume-weighted average of daily closes over 191 sessions, not a true tick-by-tick VWAP. | -4.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 5% below the average price paid since it last reported on 2026-07-30 (its 8-K), so the typical buyer over that stretch is under water. That average is $128.51 — a volume-weighted average of daily closes over 50 sessions, not a true tick-by-tick VWAP. | -5.2% |
Price levels it has turned at before
ATR last closed at $121.81 on 2026-10-08. Since 2024-10-08 it has turned at 3 prices below its last close and 13 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $121.20 | Support | 0.5% below the last close | turned there five times · 2025-11-13 to 2026-09-10 |
| $123.82 | Resistance | 1.6% above the last close | turned there twice · 2025-12-17 to 2026-07-08 |
| $117.63 | Support | 3.4% below the last close | turned there four times · 2025-11-20 to 2026-05-27 |
| $127.25 | Resistance | 4.5% above the last close | turned there 7 times · 2025-10-16 to 2026-09-16 |
| $130.70 | Resistance | 7.3% above the last close | turned there four times · 2025-04-07 to 2026-08-14 |
| $111.25 | Support | 8.7% below the last close | turned there twice · 2026-05-20 to 2026-06-08 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes above $129.56.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $124.49 and $128.69 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close below $120.74.
This reading has stood for 1 trading day, since 2026-10-08.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · MACD just crossed bullish (12/26/9) · Analyst price target recently CUT · lagging the market · Printed a bullish engulfing pair · Least volatile (2% or less typical daily range) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.50 mean, 1=Strong Buy…5=Strong Sell) — 7 analysts
- Mean price target$167.57 range $154.00 – $220.00; median $160.00
Analyst estimates, as of 2026-10-06. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ATR
- Consensus EPS estimate$1.48 next reporting period, as of 2026-10-06
- Estimate change, 30 days-$0.00286 (-0.2%) from $1.48, on 2026-09-01, 35-day window
- Readings revised upward0% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Fluctuations in raw material costs and availability","Exposure to foreign currency exchange rate volatility","Risks associated with global supply chain disruptions"]
What changed in the latest 10-Q
AI-assisted comparison of ATR's 10-Q filed 2026-07-31 against the prior one filed 2026-05-01.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-07-31) reports results for the three and six months ended June 30, 2026 and 2025, whereas the older filing (2026-05-01) reports results for the three months ended March 31, 2026 and 2025.
- Newer filing (2026-07-31) includes a line item for the six months ended June 30, 2026 and 2025 in the results of operations table.
- Newer filing (2026-07-31) states second quarter 2026 reported net sales of $1.03 billion increased 6% compared to $966.0 million in the second quarter of 2025.
- Newer filing (2026-07-31) states first six months of 2026 net sales increased 8% to $2.01 billion compared to $1.85 billion in the first six months of 2025.
- Newer filing (2026-07-31) includes a second quarter 2026 net sales change table by segment (Pharma, Beauty, Closures, Total) showing reported growth, currency effects, acquisitions, and core sales growth.
- Newer filing (2026-07-31) includes a six months ended June 30, 2026 net sales change table by segment showing reported growth, currency effects, acquisitions, and core sales growth.
- Newer filing (2026-07-31) includes a geographic net sales table for both the three months ended June 30 and the six months ended June 30 of 2026 and 2025.
- Newer filing (2026-07-31) states cost of sales as a percentage of net sales increased to 64.4% in Q2 2026 from 62.0% in Q2 2025, and to 64.3% in the first six months of 2026 from 62.1%.
- Newer filing (2026-07-31) attributes the COS increase to lower margin Pharma applications, higher operating costs, and higher input costs.
- Newer filing (2026-07-31) states SG&A increased approximately $6.6 million to $157.7 million in Q2 2026 from $151.1 million in Q2 2025, and approximately $18.9 million to $325.3 million in the first six months of 2026 from $306.4 million.
- Newer filing (2026-07-31) states depreciation and amortization expenses increased approximately $9.7 million to $79.6 million in Q2 2026 from $69.9 million in Q2 2025, and approximately $19.8 million to $155.4 million in the first six months of 2026 from $135.6 million.
- Newer filing (2026-07-31) states restructuring costs of $1.4 million and $2.5 million were recognized for the three and six months ended June 30, 2026, and $1.6 million and $3.6 million for the three and six months ended June 30, 2025.
- Newer filing (2026-07-31) states the cumulative restructuring expense incurred as of June 30, 2026 was $77.0 million.
- Newer filing (2026-07-31) begins to present restructuring costs for the three and six months ended June 30, 2026 and 2025 by segment, although the table is truncated.
- Removed:
- Older filing (2026-05-01) reports results for the three months ended March 31, 2026 and 2025, which are not present in the newer filing.
- Older filing (2026-05-01) states first three months of 2026 net sales increased 11% to $982.9 million compared to $887.3 million for the first three months of 2025.
- Older filing (2026-05-01) includes a three months ended March 31, 2026 net sales change table by segment showing reported growth, currency effects, acquisitions, and core sales growth.
- Older filing (2026-05-01) includes a geographic net sales table only for the three months ended March 31, 2026 and 2025.
- Older filing (2026-05-01) states cost of sales as a percentage of net sales increased to 64.2% in the first three months of 2026 compared to 62.1%; the newer filing covers different periods.
- Older filing (2026-05-01) attributes the COS increase to lower sales of higher margin Pharma products and lower margins on tooling sales.
- Older filing (2026-05-01) states SG&A increased approximately $12.3 million to $167.6 million in the first three months of 2026 from $155.3 million.
- Older filing (2026-05-01) states depreciation and amortization increased approximately $10.1 million to $75.7 million in the first three months of 2026 from $65.6 million.
- Older filing (2026-05-01) states restructuring costs of $1.1 million and $2.0 million for the three months ended March 31, 2026 and 2025.
- Older filing (2026-05-01) states the cumulative restructuring expense incurred as of March 31, 2026 was $75.6 million.
- Older filing (2026-05-01) includes a restructuring cost table by segment for the three months ended March 31, 2026 and 2025.
- Older filing (2026-05-01) includes additional sections on operating income, interest expense, net other income (expense), provision for income taxes, net income attributable to AptarGroup, Inc., and Pharma segment for the three months ended March 31, 2026, which are not present in the newer filing excerpt.
- Reworded:
- The results of operations percentage table changed from three-month (March 31) period data in the older filing to three- and six-month (June 30) period data in the newer filing.
- Effective tax rate changed from three months ended March 31 data (22.4% for 2026 and 25.8% for 2025) in the older filing to three months ended June 30 data (23.5% and 20.0%) and six months ended June 30 data (23.0% and 22.5%) in the newer filing.
- Adjusted EBITDA margin changed from three months ended March 31 data (19.2% for 2026 and 20.7% for 2025) in the older filing to three months ended June 30 data (20.7% and 22.6%) and six months ended June 30 data (20.0% and 21.7%) in the newer filing.
- The geographic net sales table format changed from showing only the three months ended March 31 in the older filing to showing both the three months ended June 30 and six months ended June 30 in the newer filing.
- COS discussion changed from attributing increase to lower sales of higher margin Pharma products and lower tooling margins in the older filing to attributing it to lower margin Pharma mix, higher operating costs, and higher input costs in the newer filing.
- SG&A discussion changed from Q1 2026 figures in the older filing to Q2 2026 and first half 2026 figures in the newer filing, with different dollar amounts and percentage-of-net-sales figures.
- Depreciation and amortization discussion changed from Q1 2026 figures in the older filing to Q2 2026 and first half 2026 figures in the newer filing, including different dollar amounts and different allocation to acquisitions.
- Restructuring costs discussion changed from Q1 2026 figures in the older filing to Q2 2026 and first half 2026 figures in the newer filing, with different dollar amounts and cumulative expense figures.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 7 open-market sales by insiders in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 90 days · read to 2026-10-040 buys · 7 sells ($4M) — 5 selling insiders
- Last 180 days · read to 2026-10-040 buys · 15 sells ($5M) — 7 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-09-02. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ATR's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 1 matched disclosure for ATR from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
5 institutional 13F filers reported holding ATR as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 10,735,406
- Reported value $1,344,072,960
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about ATR's institutional holders → See what each manager we track holds →
Short interest (FINRA)
ATR had 1,941,117 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
ATR had 3.05% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 4.71 days to cover at the same settlement.
- Reported short interest (shares) 1,941,117
- Short interest (% of shares outstanding) 3.05%
- Prior settlement (shares) 1,667,073
- Reported change 16.44%
- Days to cover (reported) 4.71
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Berry Global (BERY)
- Amcor (AMCR)
- West Pharmaceutical Services (WST)
- Silgan Holdings (SLGN)
- Ball Corporation (BALL)
- Sonoco Products (SON)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ATR vs…
AptarGroup is found in…
Frequently asked questions
What does AptarGroup (ATR) do?
AptarGroup is a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing, and active packaging solutions. Its products are used extensively in the pharmaceutical, beauty, personal care, home care, food, and beverage markets. The company provides specialized dispensing systems, such as pumps, closures, and aerosol valves, along with elastomeric components and connected health devices.
What sector is AptarGroup (ATR) in?
AptarGroup (ATR) is classified in the Materials sector. Its industry is packaging and dispensing solutions. It trades on NYSE.
Does ATR pay a dividend?
Yes — AptarGroup (ATR) pays a dividend, with an indicated yield of about 1.54% and at least 7 years of non-decreasing per-share dividends (SEC EDGAR XBRL) — we do not hold the year before it, so the real streak may be longer (market data, as of 2026-09-03). Informational only — not financial advice.
Who are AptarGroup's (ATR) competitors?
Notable peers of AptarGroup (ATR) include Berry Global, Amcor, West Pharmaceutical Services, Silgan Holdings and Ball Corporation. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in ATR?
Yes — we hold 1 matched STOCK Act disclosure for ATR from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is AptarGroup (ATR) overbought or oversold right now?
AptarGroup (ATR) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 40, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ATR come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.